AB-101

Artiva Biotherapeutics reported longer-term Phase 1/2 data for AlloNK cell therapy, demonstrating prolonged durability of response in patients with non-Hodgkin lymphoma.

Artiva Biotherapeutics' AlloNK in combination with rituximab demonstrated a 64% complete response rate in heavily pretreated B-cell non-Hodgkin lymphoma patients, comparable to approved autologous CAR-T therapies.

Arbutus Biopharma will present five abstracts at EASL Congress 2025, showcasing data on imdusiran and AB-101 for chronic hepatitis B treatment, including one late-breaker abstract.

Artiva Biotherapeutics has received FDA Fast Track designation for AlloNK therapy in autoimmune diseases, potentially accelerating development through enhanced agency communication and rolling application options.

The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.